Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
The question now is how to tailor dosage even more closely to fit patients’ needs. “[L]ess As Dr Thyssen further explained, “[i]t all started with the approval of the first biologic in 2017, and has been followed by the approval of other drugs, including one biologic and [three] oral drugs, in the past [one to two] years.
Let's personalize your content